-
Matthew D. Hellmann, MD, and Heather Wakelee, MD, examine and discuss key lung cancer and mesothelioma presentations from the 2017 clinical oncology meeting in Chicago.
-
In this on-demand Webcast of the live symposium in Chicago, our distinguished faculty provide insight into the key emerging and practice-changing approaches to systemic therapy in advanced HCC.
-
In this downloadable slideset, Hossein Borghaei, MS, DO, uses cases to provide insights for the management of patients with progressive advanced NSCLC using immune checkpoint inhibitors.
-
In this slideset, Gary Lyman, MD, MPH, FASCO, discusses the promise and challenges of incorporating oncology biosimilars into clinical practice.
-
In this downloadable slideset, H. Jack West, MD, uses cases to provide insights for the management of patients with newly diagnosed, advanced NSCLC using immune checkpoint inhibitors.
|
Latest Content
-
Matthew D. Hellmann, MD, and Heather Wakelee, MD, examine and discuss key lung cancer and mesothelioma presentations from the 2017 clinical oncology meeting in Chicago.
Faculty: Matthew D. Hellmann MD, Heather Wakelee MD
Released: 8/10/2017
-
| Paul Nghiem MD - 8/9/2017 |
1 comment / Last Comment: 8/10/2017 |
With avelumab now approved for MCC, what treatment options are available to patients not responding to checkpoint inhibitors? Read my thoughts on a promising new approach.
-
In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.
Faculty: Steven J. Cohen MD, Alan P. Venook MD
Released: 8/7/2017
-
Use this Interactive Decision Support Tool to get treatment recommendations from David R. Gandara, MD; Martin J. Edelman, MD, FACP; Suresh S. Ramalingam, MD; Heather Wakelee, MD; and H. Jack West, MD, for your patients with advanced NSCLC.
Date Posted: 8/7/2017
-
In this downloadable slideset, Leora Horn, MD, MSc, FRCPC, reviews current management strategies for patients with advanced NSCLC based on the most recent evidence.
Date Posted: 8/4/2017
-
In this on-demand Webcast of the live symposium in Chicago, our distinguished faculty provide insight into the key emerging and practice-changing approaches to systemic therapy in advanced HCC.
Faculty: Peter R. Galle MD, PhD, Tim F. Greten MD
Released: 7/11/2017
-
| John L. Marshall MD - 7/11/2017 |
3 comments / Last Comment: 8/8/2017 |
Should we evaluate microsatellite status in all patients with colorectal cancer, regardless of stage and treatment experience? Read my thoughts on how I approach testing in my practice.
-
In this downloadable resource, expert faculty John L. Marshall, MD, reviews key testing methods for microsatellite instability, PD-L1, and other biomarkers of response to immune checkpoint inhibitors in patients with colorectal cancer. For additional in-depth analysis, please review the accompanying CME-certified text modules, downloadable slides, and ClinicalThought commentaries for expert guidance on the optimal use of immunotherapy in colorectal cancer.
Date Posted: 6/26/2017
-
In this downloadable slideset, John L. Marshall, MD, reviews the latest clinical data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Marshall’s expert in-depth discussion.
Date Posted: 6/21/2017
-
In this module, John L. Marshall, MD, reviews practice-changing immunotherapy options for patients with metastatic colorectal cancer, as well as biomarkers that predict response to immune checkpoint inhibitors and the latest data supporting their use in GI malignancies.
Faculty: John L. Marshall MD
Released: 6/21/2017
|
|
|